Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Medtronic begins global study comparing the Endeavor and Cypher drug-eluting stents

Medtronic : 04 August, 2008  (Company News)
Medtronic has initiated the first investigational sites in the USA to participate in PROTECT, the company’s global study comparing the Endeavor and Cypher drug-eluting stents on key safety metrics, including stent thrombosis a rare but serious adverse event in which a blood clot forms inside the stent, with the potential to cause heart attack or death.
Dr Carlos Mego and his patient care team at Doctors Hospital at Renaissance in Edinburg, Texas, USA, enrolled the first US patient in the PROTECT study.

“PROTECT is the first large-scale, prospective, randomised controlled trial focused primarily on the safety of drug-eluting stents, which remains an important concern among patients and physicians alike,” said Dr William O’Neill, an interventional cardiologist and professor of medicine at the University of Miami School of Medicine in Florida. “The concern over Stent safety centres primarily on the persistent issue of Stent thrombosis, particularly after one year post-implant. This trial the largest of its kind and the only with a global scope is designed and powered to provide a thorough, long-term assessment of these stents’ safety among the diverse population of patients with coronary artery disease who constitute routine clinical practice.”

Initiated in May 2007 with the first implants in Europe, PROTECT will enroll a total of 8,800 patients, equally randomized to the Endeavor zotarolimus-eluting coronary Stent from Medtronic or Johnson and Johnson’s Cypher sirolimus-eluting coronary stent, at more than 200 medical centres globally. Enrollment through July stands at nearly 5,500 patients, more than 60 percent of the total.

Collectively, data from PROTECT augments the comprehensive ENDEAVOR clinical programme, which involves more than 21,000 patients; more than 15,000 of these patients will have received an Endeavor stent.

PROTECT sites in the USA will serve to provide the US Food and Drug Administration (FDA) with US-specific data on the post-market experience with the Endeavor stent, which received FDA approval February 1, 2008. The US sites will enroll a minimum of 1,000 patients who receive Endeavor stents through PROTECT or, if necessary, through a nonrandomized continued-access arm.

Dr Laura Mauri, an interventional cardiologist at Brigham and Women’s Hospital and the chief scientific officer of the Harvard Clinical Research Institute in Boston, explained the significance of PROTECT: “This trial, including at least 1,000 in the US arm, will help further clarify the critical balance between safety and efficacy of drug-eluting stents in real-world practice.”

Dr Mauri has published widely on Stent safety. Most recently, she was the senior author of an analysis that concluded that even “a small absolute increase in DES thrombosis compared with BMS after 1 year (>0.14 percent/year) would result in BMS being the preferred strategy for the overall PCI [percutaneous coronary intervention] population [and that] larger clinical trials with longer follow-up are needed to” evaluate safety.

PROTECT is one such trial. With 8,800 patients, it is sufficiently powered to detect a clinically significant difference in rates of Stent thrombosis between the Endeavor and Cypher stents. PROTECT’s primary endpoint is overall Stent thrombosis at three years; secondary endpoints include death and non-fatal myocardial infarction (MI), as well as customary clinical efficacy endpoints, such as target lesion revascularization and target vessel revascularization. Enrollment is expected to be complete by December 2008, with three-year data on all study patients available in 2012.

Very late Stent thrombosis (vLaST) blood clotting inside the Stent after one year post-implant arose as a safety concern with the first generation of drug-eluting stents, including the Cypher Stent and Boston Scientific’s Taxus paclitaxel-eluting coronary stent, in the fall of 2006, when the clinical trials that supported the regulatory approvals of these devices revealed a numerical increase in the rate of vLaST compared to their bare-metal Stent controls. These first-generation drug-eluting stents have been associated with an annual rate of vLaST of approximately 0.3 percent through four years of follow-up.3

The clinical trials that supported the regulatory approvals of the Endeavor Stent have shown no increase in the rate of vLaST compared with its bare-metal Stent control. The annual rate of vLaST with the Endeavor Stent in the ENDEAVOR clinical programme through four years of follow-up is 0.02 percent, with no events after two years. This observation served as the rationale for PROTECT.

“The Endeavor Stent has been so well-received worldwide, most recently in the United States, because it offers such an excellent combination of long-term safety, durable efficacy and renowned deliverability,” said Sean Salmon, vice president and general manager of the CardioVascular business unit’s Coronary and Peripheral division at Medtronic. “Given the consistency with which the Endeavor Stent has performed in clinical studies and in clinical practice, we have every confidence that PROTECT will affirm the exceptional clinical results that physicians have come to expect from a second-generation DES. We’re also confident that this trial will deliver the incremental evidence that physicians need to make the best treatment decisions on behalf of their patients with coronary artery disease.”
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo